<DOC>
	<DOCNO>NCT00447226</DOCNO>
	<brief_summary>This study examine efficacy safety lapatinib patient ErbB2 positive ovarian , gastric/esophageal adenocarcinoma , uterine serous papillary , bladder cancer .</brief_summary>
	<brief_title>Randomized Discontinuation Study Lapatinib Versus Placebo Subjects With Documented Tumor Progression After Chemotherapy , Where Approved Therapy Exists</brief_title>
	<detailed_description />
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Signed write informed consent . Age &gt; = 18 year old . Life expectancy least 12 week . Have histologically confirm ovarian , gastric/esophageal adenocarcinoma , uterine serous papillary , bladder cancer . Have ErbB2positive cancer determine Fluorescence In Situ Hybridization ( FISH ) assay . Have document tumor progression receive standard/approved chemotherapy per National Comprehensive Cancer Network ( NCCN ) guideline ( V1 ) specific cancer approve therapy exists . Have one tumor measurable medical imaging assess use Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 . Have archive tumor tissue available biomarker analysis . Have negative serum pregnancy test female childbearing potential . Any chemotherapy , major surgery , irradiation must complete least 3 week prior receive study drug ( 6 week mitomycinC nitrosourea ) subject must recover toxicity incur result previous therapy . Have gastrointestinal tract intact enough swallow assure absorption drug . Women childbearing potential must negative serum pregnancy test screening must use approved contraceptive method , appropriate ( example , intrauterine device , birth control pill , barrier device ) begin 2 week first dose investigational product 28 day final dose investigational product . Males able father child must practice adequate method birth control practice complete abstinence intercourse first dose investigational treatment one week final dose investigational treatment . Have cardiac ejection fraction within institutional range normal measure either echocardiogram multigated acquisition scan . The method cardiac evaluation must use consistently throughout study . Subjects must adequate organ function : Hematologic : absolute neutrophil count &gt; 1.5 x 109/L hemoglobin &gt; 9 g/dL platelet &gt; 75 x 109/L Hepatic : albumin &gt; 2.5 g/dL serum bilirubin &lt; 1.25 x upper limit normal aspartate aminotransferase/alanine aminotransferase &lt; 3 x ULN document liver metastasis aspartate aminotransferase/alanine aminotransferase &lt; 5 x ULN document liver metastasis Renal : serum creatinine &lt; 2.0 mg/dL OR calculate creatinine clearance1 &gt; 40 mL/min Have New York Heart Association Class III IV , cardiac disease , myocardial infarction within past 6 month , unstable arrhythmia evidence ischemia electrocardiogram . Subjects chemotherapy radiotherapy within 3 week prior enter study unresolved unstable , serious toxicity prior administration another investigational drug and/or prior cancer treatment . Concurrent treatment investigational agent participation another treatment clinical trial . Prior lapatinib therapy . ECOG Performance Status 2 great . Subjects receive concurrent chemotherapy , radiation therapy , immunotherapy , biologic therapy ( include ErbB1 and/or ErbB2 inhibitor ) , hormonal therapy treatment cancer . Concurrent treatment bisphosphonates allow . History allergic reaction attribute compound similar chemical composition ( quinazolines ) lapatinib . Concurrent treatment prohibit medication . Malabsorption syndrome , resection small bowel active , uncontrolled ulcerative colitis . Concurrent disease condition would make subject inappropriate study participation serious medical psychiatric disorder would interfere subject 's safety . Uncontrolled infection . Pregnant lactating female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Bladder Cancer</keyword>
	<keyword>ErbB2 positive</keyword>
	<keyword>Lapatinib</keyword>
	<keyword>Gastric/Esophageal Cancer</keyword>
	<keyword>Uterine Serous Papillary Cancer</keyword>
</DOC>